MedPath

COSMO PHARMACEUTICALS

🇮🇳India
Ownership
-
Employees
-
Market Cap
$1.5B
Website

UK MHRA Approves Winlevi®, First Novel Acne Treatment in 40 Years

Winlevi® (clascoterone cream 1%), the first topical androgen receptor inhibitor for acne, receives MHRA approval for patients 12 years and older in the United Kingdom.

Cosmo Pharmaceuticals Announces Strong 2024 Revenue Growth and Pipeline Advancements

Cosmo Pharmaceuticals reported a 186% increase in full-year 2024 revenue, reaching €265.7 million, driven by collaborations and AI advancements in the GI Genius platform.

© Copyright 2025. All Rights Reserved by MedPath